Daniel C. Liebler, PhD

Daniel C. Liebler is Adjunct Professor of Biochemistry at Vanderbilt University School of Medicine. He received a Ph.D. in Pharmacology at Vanderbilt and did postdoctoral training in Biochemistry and Biophysics at Oregon State University. He held tenured faculty appointments at the University of Arizona and at Vanderbilt and trained 50 doctoral students and postdoctoral fellows. Dr. Liebler’s research program focused for four decades on the interactions of chemicals with biological systems, including studies of antioxidant chemistry in biological systems and the chemistry of reactive intermediates and oxidants in inflammation and toxicity. He has been a leader in the application of mass spectrometry and proteomic technology to biochemistry, chemical biology, cancer biology and drug discovery and development. Dr. Liebler published 214 peer reviewed papers and two books and was issued four US and international patents. Dr. Liebler served on over two dozen advisory panels for the National Institutes of Health, the National Research Council and academic research centers across the United States. He also served on the Expert Panel for the Cosmetic Ingredient Review and the Expert Panel for Fragrance Safety. He has been elected a Fellow of the American Association for the Advancement of Science and of the American Chemical Society. In 2017, Dr. Liebler founded Protypia, Inc (acquired by Inotiv in 2022) to provide a mass spectrometry platforms for drug development for the pharmaceutical industry in diverse therapeutic areas.